Effects of glatiramer acetate on spasticity in previously interferon-β-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: A prospective, nonrandomized, open-label, uncontrolled, observational pilot study
- 30 June 2010
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 32 (6) , 1061-1066
- https://doi.org/10.1016/j.clinthera.2010.06.005
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetateMultiple Sclerosis Journal, 2010
- Prevalence and treatment of spasticity reported by multiple sclerosis patientsMultiple Sclerosis Journal, 2004
- Treatments for spasticity and pain in multiple sclerosis: a systematic reviewHealth Technology Assessment, 2003
- Comparison of glatiramer acetate (Copaxone®) and interferon β-1b (Betaferon®) in multiple sclerosis patients: an open-label 2-year follow-upJournal of the Neurological Sciences, 2002
- Quantitative measures of spasticity in post-stroke patientsClinical Neurophysiology, 2000
- Translation and validation of arthritis outcome measures into spanishArthritis & Rheumatism, 1995
- Treatment of spasticity with botulinum toxin: A double‐blind studyAnnals of Neurology, 1990
- Intrathecal Baclofen for Severe SpasticityAnnals of the New York Academy of Sciences, 1988
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- Studies with different types of visual analog scales for measurement of painClinical Pharmacology & Therapeutics, 1983